|
|
Article: Collegium Pharmaceutical Announces FDA Filing for AllerNase(TM), a Nasal Inhaled Steroid for the Treatment of Allergic Rhinitis.
- Article from:
- Business Wire
- Article date:
- April 8, 2008
CopyrightCOPYRIGHT 2008 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
CUMBERLAND, R.I. -- Collegium Pharmaceutical, Inc., a specialty pharmaceutical company with a focus on respiratory and CNS disorders, today announced that it filed a Supplemental New Drug Application (sNDA) with the U.S. Federal Drug Administration (FDA) for the approval of AllerNase[TM] (triamcinolone acetonide, USP) Nasal Spray, 50 mcg, an aqueous based intranasal steroid indicated for the once daily treatment of nasal symptoms associated with both seasonal and perennial allergic rhinitis in adults and children twelve years of age and older.
Background:
Collegium acquired the rights, title and interest in Tri-Nasal[R] (triamcinolone acetonide, USP) ...